Company Overview
CVRx, Inc., a commercial-stage medical device company, engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases in the United States, Germany, and internationally. The company offers Barostim, an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery to counteract decreased baroreceptor signaling, and provides baroreflex activation therapy, which links the cardiovascular system to the autonomic nervous system. It sells its products through direct sales force, sales agents, and independent distributors. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Why Investors Should Care
Revenue has grown at a 56.4% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $56.65M (+10.4% YoY); net profit $-53.31M.
- Trailing 12 Months Year-on-year growth — revenue +15.6%.
- 5-Year Trend Long-term compounding — revenue CAGR 56.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 56.40% |
| 1 Year: | 15.60% |
Stock Price Performance
| 1 Year: | -81.61% |
| 6 Months: | -81.61% |
| 3 Months: | -70.90% |
| 1 Month: | -43.87% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)30.48 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 56.4% over 5 years.
CONS
- Trading 86.9% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CVRX CVRx, Inc. R2KR3KPHARMA | 1.42 | -0.72 | $37.83M | 0.00% | -56.04% | -133.45% | 56.40% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.25M | 997.00K | 2.86M | 3.12M | 3.40M | 4.08M | 5.03M | 6.19M | 7.98M | 9.50M | 10.51M | 10.77M | 11.81M | 13.37M | 12.35M | 13.59M | 14.69M | 14.77M | 15.71M |
| Gross Profit | 905.00K | 785.00K | 1.99M | 2.21M | 2.52M | 3.13M | 3.83M | 4.85M | 6.65M | 7.98M | 8.82M | 9.15M | 9.91M | 11.12M | 10.31M | 11.45M | 12.75M | 12.88M | 13.72M |
| Operating Income | -3.06M | -3.04M | -4.22M | -5.67M | -7.29M | -9.91M | -11.01M | -10.13M | -12.16M | -11.75M | -9.53M | -22.23M | -13.97M | -13.01M | -13.44M | -14.38M | -12.27M | -12.16M | -13.02M |
| Net Income | -3.67M | -3.23M | -8.63M | -17.75M | -6.13M | -9.99M | -11.07M | -9.83M | -11.37M | -11.65M | -9.01M | -22.19M | -14.03M | -13.10M | -13.77M | -14.74M | -12.87M | -13.12M | -14.04M |
| Diluted EPS | - | - | -23.92 | -48.48 | -0.30 | -0.49 | -0.54 | -0.48 | -0.55 | -0.56 | -0.43 | -1.04 | -0.65 | -0.57 | -0.53 | -0.57 | -0.49 | -0.50 | -0.53 |
| R&D Expense | 2.13M | 1.50M | 1.75M | 2.25M | 1.70M | 2.26M | 2.35M | 2.29M | 3.42M | 3.28M | 2.70M | 3.06M | 2.77M | 2.50M | 2.52M | 2.47M | 3.15M | 3.08M | 3.13M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | 6.05M | 13.04M | 22.47M | 39.30M | 51.29M | 56.65M |
| Gross Profit | 4.61M | 9.40M | 17.47M | 33.04M | 42.96M | 48.34M |
| Operating Income | -11.51M | -25.97M | -42.53M | -43.10M | -59.49M | -51.27M |
| Net Income | -14.11M | -43.08M | -41.43M | -41.20M | -59.97M | -53.31M |
| Diluted EPS | - | -4.16 | -2.02 | -1.99 | -2.65 | -2.04 |
| R&D Expense | 6.41M | 7.50M | 9.95M | 11.63M | 11.13M | 11.13M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 64.78M | 152.55M | 124.94M | 115.23M | 133.41M | 104.79M |
| Total Equity | -279.04M | -293.24M | 145.96M | 109.18M | 75.95M | 71.06M | 39.32M |
| Cash & Equivalents | - | 59.11M | 142.07M | 106.19M | 90.57M | 105.93M | 75.71M |
| Long Term Debt | - | 19.28M | 0 | 6.75M | 29.22M | 49.27M | 49.51M |
| Total Liabilities | - | 28.03M | 6.59M | 15.76M | 39.28M | 62.36M | 65.47M |
| Current Liabilities | - | 7.98M | 5.91M | 8.09M | 7.86M | 10.76M | 13.32M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -16.10M | -27.73M | -42.68M | -39.02M | -39.14M | -40.17M |
| Investing Cash Flow | -311.00K | -1.18M | -685.00K | -591.00K | -1.36M | -580.00K |
| Financing Cash Flow | 49.78M | 111.88M | 7.49M | 23.98M | 55.87M | 10.52M |
| Capital Expenditure | -311.00K | -1.18M | -685.00K | -591.00K | -1.36M | -580.00K |
| Free Cash Flow | -16.41M | -28.91M | -43.36M | -39.61M | -40.51M | -40.75M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | 76.2% | 72.1% | 77.8% | 84.1% | 83.8% | 85.3% |
| Operating Margin % | -190.2% | -199.2% | -189.3% | -109.7% | -116.0% | -90.5% |
| Net Margin % | -233.1% | -330.5% | -184.4% | -104.8% | -116.9% | -94.1% |
| ROE % | 4.8% | -29.5% | -37.9% | -54.2% | -84.4% | -135.6% |
| ROCE % | -20.3% | -17.7% | -36.4% | -40.1% | -48.5% | -56.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 15.11% | 4.02M | $6.36M |
| 2 | NEA Management Company, LLC | 7.34% | 1.95M | $3.09M |
| 3 | Blackrock Inc. | 4.67% | 1.25M | $1.97M |
| 4 | Royal Bank of Canada | 4.63% | 1.23M | $1.95M |
| 5 | GSK plc | 3.78% | 1.01M | $1.59M |
| 6 | Vanguard Capital Management LLC | 3.42% | 910.58K | $1.44M |
| 7 | Silvercrest Asset Management Group, LLC | 3.30% | 878.11K | $1.39M |
| 8 | Geode Capital Management, LLC | 1.65% | 440.79K | $696.44K |
| 9 | Pfm Health Sciences, Lp | 1.39% | 369.57K | $583.92K |
| 10 | State Street Corporation | 1.38% | 366.35K | $578.84K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CVRX
CVRx Inc(CVRX) Stock Options Chain | Quotes & News - Moomoo
<a href="https://news.google.com/rss/articles/CBMiggFBVV95cUxOcUZIVDVtTENzZGs3ZGpVTnVKejdwMEFrUmVfR3RpaXRnWGptanJVWkFVTVlkcS1mS1VoSVNtZzVqa00yc3ctb01wTmZodW9aS2Z4THFabGxUQ0ZyamVvVVZ4ZFdGZXI2emt2TGdMX2ZoRWNSLTRmRkMyQlcwZ0xPQWVR?oc=5" target=…
CVRX Dec 2026 15.000 call (CVRX261218C00015000) stock historical prices and data - Yahoo Finance UK
<a href="https://news.google.com/rss/articles/CBMicEFVX3lxTE1fVDdKQWljb29EdHZfYWg4bHprdkx3VThneGVoV1NubkFPTXhtUDNic21LSHZXX1hSUHZBSjRIUVpnSjlJZVlsUy1lcDJuTmNGZFpURjZ3ZzFCcEg1XzI5YjhQbDJoS1dzb21YUDA0VEs?oc=5" target="_blank">CVRX Dec 2026 15…
CVRx to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call on November 5, 2026 - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxQdEZqcjZUaF80dC1PT3c2U3FVbzJkWUNuR3JWZXNLTVUxNlV2cGtianpGc3A4ZGMtMW9zRExybVJrb3dwalI2elkwOVljTTJzUkRxOW1uWXROLXlyUWtwZWV4eTJhNkhsaVJ1dHVzMWlfcDhONURibm1wSXRhUy1HcG51OXJwbkNtMVdLOX…
CVRX Nov 2026 2.500 call (CVRX261120C00002500) stock price, news, quote and history - Yahoo Finance UK
<a href="https://news.google.com/rss/articles/CBMiZkFVX3lxTE0taV9rUXVkdTNCMWozWjhESWVCZ3p3MUFOOWt3Njdhb2hNendaNUxuc1c2VHVPUUZtYlc2WEl2RHZ4RFhrM0ZJQU9FZU1CSWxhTEFDUDZicmxhQmc4LU42V0dHVVdkdw?oc=5" target="_blank">CVRX Nov 2026 2.500 call (CVR…
CVRX Jan 2027 10.000 put (CVRX270115P00010000) stock price, news, quote and history - Yahoo Finance UK
<a href="https://news.google.com/rss/articles/CBMiZkFVX3lxTE1yellSMzA2QVVlTnY4cmdSMnpNTjVRWWY5b1ZTZjhDUkxaRV9udkR0UU1DZTZINE9SZkN1VkNUTkpNWUFyLUhpQ0N4STJiRTUzUUp6R2lOMFhhRjRKOFcwaEE0dEQzZw?oc=5" target="_blank">CVRX Jan 2027 10.000 put (CVR…
CVRX Oct 2026 5.000 put (CVRX261016P00005000) stock historical prices and data - Yahoo Finance UK
<a href="https://news.google.com/rss/articles/CBMicEFVX3lxTE02NXdfVFFuLUM4Z3I1QUVUX0F5a1V3em1falZpWUt2NDJ3SjV1V0JrRFl5MFVleXNpcE44MGJoZlB0Q3Utcy1XUE95Z1hkVXpxSjZvbXVkaXlhZFdTMEp1Q1NPX1RBZDBpX2lsYk8yLTg?oc=5" target="_blank">CVRX Oct 2026 5.…
CVRX — Frequently Asked Questions
What is the current share price of CVRx, Inc. (CVRX)?
As of 2026-10-23 16:27 PDT, CVRx, Inc. (CVRX) trades at $1.42 on NasdaqGS. Its 52-week range is $1.30 to $10.81.
What is the market capitalisation of CVRX?
CVRx, Inc. (CVRX) has a market capitalisation of $37.83M on NasdaqGS.
What is the P/E ratio of CVRX?
CVRX trades at a trailing price-to-earnings (P/E) ratio of -0.72. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 2.11.
What is the return on equity (ROE) of CVRX?
CVRX has a return on equity (ROE) of -133.45%. Its return on capital employed (ROCE) is -56.04%.
Is CVRX a good stock to buy?
This page provides a data-driven analysis of CVRx, Inc. (CVRX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.